ReviewCancers2015
Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?
Review in Cancers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease.The Journal of clinical endocrinology and metabolism · 2022Trial
- Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies.British journal of clinical pharmacology · 2026Article
- Review
- Is the Development of Hypo-Gammaglobulinemia Associated with Better Treatment Response in Patients with Rheumatoid Arthritis Using Rituximab?Journal of clinical medicine · 2025Article
- Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes.Clinical immunology communications · 2025Article
- Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab.Journal of viral hepatitis · 2025Review
- Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab.International journal of molecular sciences · 2025Article
- Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Secondary antibody deficiencies: what's around the corner?Frontiers in immunology · 2025Review
- Association between immunosuppressive medications and COVID-19 hospitalisation and death: a retrospective cohort study.BMJ open · 2024Article
- Effects of different doses of rituximab on immunoglobulin levels in high-risk pediatrics with Burkitt's lymphoma.Annals of hematology · 2024Article
- Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.Virology journal · 2024Article
- B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2024Review
- Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.Frontiers in immunology · 2024Review
- SARS-CoV-2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis.JAAD international · 2022Article
- Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Observational
- Hepatotoxicity during legacy cancer chemotherapy in patients infected with hepatitis C virus: A retrospective cohort study.Canadian liver journal · 2022Article
- Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies.Paediatric drugs · 2021Review
- Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.JAMA network open · 2021Article
- A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications.Frontiers in pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab, an anti CD20 monoclonal antibody, is widely used in the treatment of B-cell malignancies in adults and increasingly in pediatric patients. By depleting B-cells, rituximab interferes with humoral immunity. This review provides a comprehensive overview of immune reconstitution and infectious complications after rituximab treatment in children and adolescents. Immune reconstitution starts usually after six months with recovery to normal between nine to twelve months. Extended rituximab treatment results in a prolonged recovery of B-cells without an increase of clinically relevant infections. The kinetic of B-cell recovery is influenced by the concomitant chemotherapy and the underlying disease. Intensive B-NHL treatment such as high-dose chemotherapy followed by rituximab bears a risk for prolonged hypogammaglobulinemia. Overall transient alteration of immune reconstitution and infections after rituximab treatment are acceptable for children and adolescent without significant differences compared to adults. However, age related disparities in the kinetic of immune reconstitution and the definitive role of rituximab in the treatment for children and adolescents with B-cell malignancies need to be evaluated in prospective controlled clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.